Shares of Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the sixteen research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $48.64.
Several brokerages recently issued reports on LEGN. UBS Group reissued a “buy” rating and set a $65.00 target price on shares of Legend Biotech in a research note on Monday, September 28th. Barclays reduced their price objective on shares of Legend Biotech from $68.00 to $61.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 11th. HC Wainwright reissued a “buy” rating on shares of Legend Biotech in a report on Friday, October 30th. Wall Street Zen raised shares of Legend Biotech from a “hold” rating to a “buy” rating in a research note on Saturday, November 14th. Finally, Benchmark reiterated a “buy” rating on shares of Legend Biotech in a report on Tuesday, July 28th.
Get Our Latest Research Report on LEGN
Legend Biotech Stock Performance
Legend Biotech (NASDAQ:LEGN – Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. The company had revenue of $359.50 million for the quarter, compared to the consensus estimate of $361.46 million. Legend Biotech had a negative net margin of 0.02% and a negative return on equity of 0.03%. The firm’s revenue was up 32.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.05) earnings per share. On average, equities research analysts expect that Legend Biotech will post -0.02 EPS for the current year.
Insider Activity at Legend Biotech
In other news, CFO Carlos E. Santos sold 5,430 shares of the firm’s stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $9.14, for a total value of $49,630.20. Following the completion of the sale, the chief financial officer directly owned 14,246 shares of the company’s stock, valued at $130,208.44. This trade represents a 27.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Corazon (Corsee) D. Sanders sold 27,370 shares of the business’s stock in a transaction on Tuesday, September 29th. The shares were sold at an average price of $9.46, for a total transaction of $258,920.20. Following the transaction, the director owned 52,731 shares in the company, valued at $498,835.26. This trade represents a 34.17% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.02% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Parallel Advisors LLC boosted its stake in shares of Legend Biotech by 173.9% in the first quarter. Parallel Advisors LLC now owns 2,084 shares of the company’s stock worth $38,000 after acquiring an additional 1,323 shares during the last quarter. Toth Financial Advisory Corp purchased a new stake in shares of Legend Biotech during the third quarter worth $50,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Legend Biotech in the second quarter valued at about $92,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in Legend Biotech during the third quarter worth about $136,000. Finally, Nykredit A S acquired a new position in Legend Biotech during the second quarter worth about $162,000. 70.89% of the stock is currently owned by hedge funds and other institutional investors.
About Legend Biotech
Legend Biotech is a biotechnology company focused on developing cell therapies for cancer, with an emphasis on chimeric antigen receptor (CAR) T-cell treatments. Founded in 2014, the company is headquartered in Somerset, New Jersey, and conducts research and development activities in the United States and China. Its lead product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend developed the therapy with Janssen, now part of Johnson & Johnson’s Innovative Medicine business, which collaborates on its commercialization.
Featured Articles
- Five stocks we like better than Legend Biotech
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
